On April 20, 2023 ISA reported that it will be participating and presenting in person, at the following scientific and business conferences in May and June of 2023 (Press release, ISA Pharmaceuticals, APR 20, 2023, View Source [SID1234630352]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ISA’s versatile synthetic long peptide (SLP) immunotherapy platform is yielding multiple, highly promising clinical stage immunotherapeutics for the treatment of different cancer types and infectious diseases. It has demonstrated to be best-in-class technology to strongly and specifically activate the human immune system. SLP immunotherapeutics have been tested in multiple human clinical proof-of-concept and phase 2 trials, both as monotherapies and in combination with checkpoint inhibitors or standard-of-care chemotherapy.
LSX World Congress
Date: 3-4 May 2023, London, UK
Attending: Gerben Moolhuizen
CIMT 2023
Date: 3-5 May 2023, Mainz, Germany
Poster presentation to be announced
Attending: Esmé van der Gracht
Bio€quity Europe
Date: 14-16 May 2023, Dublin, Ireland
Company Presentation by: Gerben Moolhuizen
Attending: Gerben Moolhuizen, Anton Mat
ASCO Annual Meeting
Date: 2-6 June 2023, Boston, US
Poster presentation to be announced
Attending: Gerben Moolhuizen, Cornelis (Kees) Melief, Leon Hooftman
BIO International Convention
Date: 5-8 June, Boston, US
Attending: Anton Mat
EASL Congress
Date: 21-24 June 2023, Vienna, Austria
Attending: Anton Mat
If you would like to meet with the ISA Pharmaceuticals team at any of the above events, please contact us at [email protected]. For more information.